Magnetic resonance imaging (MRI) at the site of injection of a contaminated lot of a steroid drug to treat symptoms such as back pain resulted in earlier identification of patients with probable or confirmed fungal spinal or paraspinal infection, allowing early initiation of medical and surgical treatment, according to a study in the June 19 issue of JAMA.
Fungal contamination of methylprednisolone prepared by a compounding pharmacy resulted in an unprecedented multistate outbreak of meningitis in the fall of 2012, according to background information in the article. Initially, these injections were complicated by meningitis. Within six weeks of the outbreak, meningitis became less frequent and localized spinal and paraspinal infections became the principal manifestations of contaminated steroid injections. In contrast to the relatively brief period in which meningitis cases appeared, a steady stream of spinal and paraspinal infections continue to present long after the injections were administered. Because patients received these injections to treat back pain or neuropathic symptoms, the presentation of a slowly developing spinal or paraspinal infection has been obscured.
Anurag N. Malani, MD, of St. Joseph Mercy Hospital in Ann Arbor, Mich., and colleagues conducted a study to determine if patients who had not presented for medical care but who had received contaminated methylprednisolone developed spinal or paraspinal infection at the injection site detected using contrast-enhanced MRI screening. There were 172 patients who had received an injection of methylprednisolone from a highly contaminated lot at a pain facility but had not presented for medical care related to adverse effects after the injection. Screening MRI was performed between November 2012 and April 2013.
Of the 172 patients screened, 36 (21 percent) had an abnormality in their MRI. Thirty-five of the 36 patients with abnormal MRIs met the Centers for Disease Control and Prevention (CDC) case definition for probable (17 patients) or confirmed (18 patients) fungal spinal or paraspinal infection. All 35 patients were treated with antifungal agents; 24 required surgical intervention.
At the time of surgery, 17 of 24 patients (71 percent), including five patients who denied having symptoms, had laboratory evidence of fungal infection, the authors write.
Data were obtained from 115 patients regarding the presence of new or worsening back or neck pain, radiculopathy, or lower-extremity weakness Thirty-five of the 115 patients (30 percent) had at least 1 of these symptoms.
Our findings support obtaining contrast-enhanced MRI of the injection site in patients with persistent back pain even when their pain disorder has not worsened, the researchers write. A proactive outreach to patients receiving injections from a highly contaminated lot is needed. Magnetic resonance imaging may detect infection earlier in some patients, leading to more efficacious medical and surgical treatment and improved outcomes, the researchers conclude.
Reference: JAMA. 2013;309(23):2465-2472